CN104645178A - Drug for intrapleural hyperthermic perfusion therapy - Google Patents
Drug for intrapleural hyperthermic perfusion therapy Download PDFInfo
- Publication number
- CN104645178A CN104645178A CN201510037776.5A CN201510037776A CN104645178A CN 104645178 A CN104645178 A CN 104645178A CN 201510037776 A CN201510037776 A CN 201510037776A CN 104645178 A CN104645178 A CN 104645178A
- Authority
- CN
- China
- Prior art keywords
- parts
- drug
- hydrothorax
- fructus
- intrapleural
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a drug for intrapleural hyperthermic perfusion therapy, and is used for solving the therapy problem of cancerous hydrothorax. The drug is characterized by being prepared from the medicinal raw materials including rhizoma arisaematis, folium eucalypti, denseflower bulbophyllum herb, mussel, fragrant sarcococca herb, periostracum cicada, motherwort fruit, sweet clover, kaempferiae, fruits of polygonum orientale and sargassum fusiforme. Clinical experiments prove that the drug disclosed by the invention has good curative effect and higher safety for treating cancerous hydrothorax; and therefore, the drug is worthy of being clinically applied and popularized.
Description
Technical field
The present invention relates to the field of Chinese medicines, be specifically related to a kind of medicine for thoracic cavity thermo-chemotherapy.
Background technology
Thermo-chemotherapy is a kind of new therapy of thermotherapy application for the treatment of tumor, its principle utilizes physical energy to heat medicinal liquid filling to tumor locus, tumor tissues temperature is risen to and effectively treats temperature, and maintain certain hour, utilize normal structure and tumor cell to the difference of temperature tolerance, reach the therapeutic purposes that can make apoptosis of tumor cells, again not damaging normal tissue.
For the tumor patient that cancerous hydrothorax occurs, be full of liquid in pleural space, while derivation hydrothorax, carrying out thoracic cavity thermo-chemotherapy is a kind of new approaches and theory in recent years.The infusion liquid of current thoracic cavity thermo-chemotherapy mainly contains two kinds: one is normal saline, and it controls hydrothorax poor in timeliness, and relapse rate is high; Another kind is chemotherapeutics, as cisplatin, nedaplatin etc., its mechanism of action is localize cytotoxic and promotes pleural adhesion, but often occur owing to promoting adhesion excessive clinically, cellulose is deposited on pleura in a large number, blood capillary in pleura and fibroblast grow in cellulose, become granulation tissue, machine changes into as thicker, fine and close peplos, the pleura fibre board of forming machine, extensive, hard pleura fibre board parcel lung tissue, lack flexibility, thorax limitation of activity, respiratory function seriously goes down, and increases hydrothorax recurrent.
Therefore still lack a kind of effect affirmative clinically, effectively can improve respiratory function, the thoracic infusion liquid of relapse rate can be reduced.
In prior art, the many references of cancerous hydrothorax " fluid-retention in the chest and hypochondrium " are fluid-retention in the chest and hypochondrium, and the rule for the treatment of mostly is " drink of dispelling of relieving oedema or abdominal distension through diuresis or purgation ", reuses Radix Kansui, the Radix Euphorbiae Pekinensis, Flos Genkwa, as Shizao Tang or control birth pellet.But said medicine is oral drugs, through gastrointestinal absorption, onset is slow.And relieve oedema or abdominal distension through diuresis or purgation dispel drink object be to eliminate hydrothorax as soon as possible, the basis of this kind of scheme proposition is pure expectant treatment, when hydrothorax cannot be extracted out, can only be eliminated by its penetration enhancement, but in existing medical condition, can extracting out in time of hydrothorax, and " drink of dispelling of relieving oedema or abdominal distension through diuresis or purgation " method utilizes the method for dehydration to concentrate cancerous hydrothorax, in fact can aggravate cellulose in blood, albumen in epipleural deposition, and cause pleural thickening adhesion, increase the weight of dyspnea.Therefore, need to look for another way, find one and can be used in the appearance of containment cancerous hydrothorax, and fibre machine incidence rate can be reduced, improve respiratory symptom, reduce the medicine of relapse rate.
Compared with prior art, the present invention has following characteristics:
1, this prescription dispel local expectorant coagulate for core, therefore with Eriocheir sinensis seven, Fructus Piperis Longi for monarch, experimentation shows, perfusion pleura reaction can be alleviated while Eriocheir sinensis seven, Fructus Piperis Longi partner treatment hydrothorax, the mechanism of its effect may be too drastic to reducing local immunity with " Eriocheir sinensis seven, Fructus Piperis Longi " medicine, reduces plasma plasminogen expression relevant.Its results of animal is: use Eriocheir sinensis seven and Fructus Piperis Longi mixing water decoct (Eriocheir sinensis seven: Fructus Piperis Longi=1:3) 0.6g(crude drug)/ml is used for rabbit hydrothorax model thoracic infusion, evaluate pleura reaction (0 degree: all coating simple squamous mesothelial cell of visceral layer and parietal pleura, does not change; I degree: visceral layer and parietal pleura are coated to simple squamous mesothelial cell and transfer simple cuboidal epithelium cell to; II degree: visceral layer and parietal pleura part are coated to and transfer simple cuboidal epithelium cell to from simple squamous mesothelial cell, and part transfers stratified epithelium cell to from simple squamous epithelium cell, and below it, connective tissue proliferation causes pleural thickening; III degree: visceral layer and parietal pleura transfer stratified epithelium cell to from simple squamous epithelium cell, below it, connective tissue proliferation causes pleura obviously to thicken), result shows, and experimental group III degree pleura reaction incidence rate (2/10) is starkly lower than saline control group (6/10);
2, Fructus Carthami tinctorii of fetching water falls apart blood eliminating mass, and Folium eucalypti globueli (Eucalyptus globulus Labill.), Hai Qianzaoization are turbid, accelerates pleura connective tissue vasoganglion hypertrophy, in the hope of closed-chest as soon as possible, reduces hydrothorax generation;
3, Periostracum Cicadae walks the venation of lung, and ventilation is passed unimpeded, and its water extract slightly can suppress the effect of acetylcholine, and heavy dose of Periostracum Cicadae can slightly excitedly breathe for anesthetized dog; Delicate fragrance Laurus nobilis that is upper with the fruit of the husky Rhizoma Zingiberis Recens of circulation of qi promoting, removing obstruction in the collateral to relieve pain, regulating QI to relieve pain coordinates, mitigation pleura zest pain, slows down to resist the Breathing movement caused due to thoracic wall illness;
4, Mytilus is the in love product of flesh and blood, and can remove irritable feverish sensation in the chest, the active component Yi Bei Duo Huo Su (MSM) contained in Mytilus, MSM can reduce collagen-induced Platelet Aggregation in Rabbits rate and aggregation velocity;
5, hydrothorax amount is larger, can add Fructus Leonuri diuretic eliminating stagnation, Melilotus suaveolens Ledeb.ization is turbid to reduce hydrothorax generation.
Summary of the invention
Technical assignment of the present invention is for above the deficiencies in the prior art, provides a kind of curative effect certainly and the little medicine for thoracic cavity thermo-chemotherapy of side effect.
The technical scheme that the present invention solves its technical problem is: a kind of medicine for thoracic cavity thermo-chemotherapy, it is characterized in that being prepared from by the crude drug of following weight proportion: Eriocheir sinensis 71 ~ 3 parts, Fructus Piperis Longi 6 ~ 9 parts, Fructus Polygoni Orientalis 1 ~ 5 part, Folium eucalypti globueli (Eucalyptus globulus Labill.) 12 ~ 20 parts, extra large 10 ~ 25 parts, alizarin algae, Herba Bulbophylli Odoratissim 3 ~ 12 parts, husky Rhizoma Zingiberis Recens 12 ~ 20 parts, Sarcococca ruscifolia Stapf 3 ~ 12 parts, Periostracum Cicadae 12 ~ 20 parts, Mytilus 3 ~ 12 parts.
Larger for hydrothorax amount, Fructus Leonuri 12 ~ 20 parts, Melilotus suaveolens Ledeb. 12 ~ 20 parts can be added.
Wherein said: Eriocheir sinensis seven is root stock and the root of Liliaceae Smilacina plant tube flower Radix et rhizoma smilacinae japonicae Smilacina henryi (Baker) Wang et Tang.Nature and flavor are sweet, temperature.Merit can temperature male wind-supplying kidney, expelling wind and removing dampness, and blood circulation promoting and blood stasis dispelling, reduces phlegm; Eliminating stagnation.
Fructus Piperis Longi, the nearly ripe or mature fruit cluster of the drying for Piperaceae plant Fructus Piperis Longi Piper longum L..Nature and flavor are pungent, heat.Return stomach, large intestine channel.Merit can warming spleen and stomach for dispelling cold, therapeutic method to keep the adverse QI flowing downwards pain relieving.
Fructus Polygoni Orientalis is the dry mature fruit of polygonaceae plant smartweed Polygonum orientale L..Salty, be slightly cold.Return liver, stomach warp.Merit can be fallen apart blood eliminating mass, removing food stagnancy pain relieving.
Folium eucalypti globueli (Eucalyptus globulus Labill.) is Folium eucalypti globueli (Eucalyptus globulus Labill.), is the leaf of myrtle Eucalyptus globulus Labill Eucalyptus globulus Labill..Toil, cool.Merit can dispelling wind to relieve the exterior syndrome; Heat-clearing and toxic substances removing; Phlegm-eliminiating and qi-regulating; Killing parasites for relieving itching.
Hai Qianzao is Sargassaceae plant Alga Sgrgassi Enerves Sargassum enerve C.Ag., Sargassum henslowianum Sargassum henslowianum C.Ag., sargassum thunbergii Sargassum thunbergii(Mert.) O.Kuntze or Sargassum phyllocystum Tseng et Lu,Sargassum horneri (Turn.) C. Ag. (Fucus horneri (Turn.)C.Ag.,Spongocarpus horneri Kutz.) argassum horneri(Turn.) frond of C. Ag.Nature and flavor are salty; Cold.Return liver; Stomach; Kidney channel.Merit can hard masses softening and resolving; Removing heat-phlegm.
Periostracum Cicadae is institute's exuviae shell after the larva emergence of cicada Cryptotympana atrata Fabr. Cryptotympana pustulata Fabricius.Nature and flavor are sweet, cold.Enter lung, Liver Channel.Merit can be fallen apart wind heat, and throat, moves back corneal nebula, arresting convulsion epilepsy.
Herba Bulbophylli Odoratissim is the orchid family Bulbophyllum platymiscium extremely fragrant Bulbophyllum Bulbophyllum odoratissimum (Swartz) Lindl., with all herbal medicine.Nature and flavor are sweet; Light; Cool.Return lung; Liver; Kidney channel.Merit can moistening the lung and resolving phlegm; Removing obstruction in the collateral to relieve pain.
Sha Jiang is the rhizome of zingiberaceous plant Rhizoma Kaempferiae Kaempferia galanga L.; Nature and flavor are pungent, temperature.Return stomach warp.In the feasible temperature of merit, help digestion, pain relieving.
Sarcococca ruscifolia Stapf is Buxaceae Sarcococca plant open country fan flower Sarcococca ruscifolia Stapf root.Nature and flavor are pungent, bitter, flat.Merit can regulating QI to relieve pain, dispelling, collateral-activating.
Mytilus is Mollusca lamellibranchiata Mytilidae Mytilus crassitesta Lischke Mytilus crassitesta Lischke; Mussel M. edulis L.; Perna uiridis (Linnaeus) M. (Chloromya) smaragdinus Chemnitz; Flat top clam Modiolus modiolus (L.); Philippine pushes up clam M. philippinarum Hanley partially, is used as medicine with meat.Nature and flavor are sweet, temperature.Merit can invigorating the liver and kidney; Benefiting essence-blood; Disappear goiter; Remove irritable feverish sensation in the chest, fall borax poison.
Melilotus suaveolens Ledeb. is pulse family sweet clover Melilotus suaveolens Ledeb. Melilotus suaveolens Ledeb., with all herbal medicine; Nature and flavor are pungent, flat.Merit can eliminating turbid pathogen with aromatics, preventing the attack (or recurrence) of malaria.
Fructus Leonuri is the dry mature fruit of labiate Herba Leonuri Leonurus japonicus Houtt..Nature and flavor are pungent, bitter, are slightly cold.GUIXIN bag, Liver Channel.Merit can promoting blood flow to regulate menstruation, liver heat removing and eyesight improving.
Detailed description of the invention
Below in conjunction with practical situation, the specific embodiment of the present invention is elaborated.
Embodiment 1, crude drug weight proportion: Eriocheir sinensis 72 parts, Fructus Piperis Longi 8 parts, Fructus Polygoni Orientalis 2 parts, Folium eucalypti globueli (Eucalyptus globulus Labill.) 16 parts, extra large 16 parts, alizarin algae, Herba Bulbophylli Odoratissim 6 parts, Sarcococca ruscifolia Stapf 6 parts, husky Rhizoma Zingiberis Recens 16 parts, Periostracum Cicadae 16 parts, Mytilus 6 parts.
The preparation method of embodiment 1 is:
(1) load diafiltration still after above-mentioned raw materials being screened roguing, metering, mixing, pulverizing, add 3 times of raw material weights, volumetric concentration is the ethanol of 98%, be heated to 60 DEG C, heat and carry out diafiltration after 5 hours;
(2) percolate that step 1 obtained injects distillating still and concentrates, and distillate returns and injects diafiltration still and continue diafiltration, and control filtering velocity 120 Hao and Sheng ∕ and to divide kilogram, circulation diafiltration is extracted, after 5 hours filtrate color unchanged till, filtrate discharging is deposited, and filtering residue is deposited for subsequent use;
(3) after filtering residue dealcoholysis step 2 obtained, add 3 times amount deionized waters and soak after 5 hours and carry out circulation diafiltration, filtering velocity 100 milli rises ∕ and to divide kilogram, and lasting 8 hours, till treating that filtrate is colourless, filtrate discharging was deposited;
(4) the filtrate mixing will obtained in step 2, step 3, the medicinal carbon adding 1% stirs, and is heated to 100 DEG C, filters;
(5) step 4 gained filtrate is filtered with 0.22 μm of microporous filter membrane.
In order to obtain better clarity, step 4 also can be: by the filtrate mixing obtained in step 2, step 3, the medicinal carbon adding 1% stirs, and is heated to 100 DEG C, cold preservation 30min at filtering latter 2 DEG C, takes out and filters.The 1% described percentage by weight that refers to, described medicinal carbon is through 150 DEG C of dry activation 4h.
Embodiment 2, crude drug weight proportion: Eriocheir sinensis 71 parts, Fructus Piperis Longi 6 parts, Fructus Polygoni Orientalis 1 part, Folium eucalypti globueli (Eucalyptus globulus Labill.) 20 parts, extra large 10 parts, alizarin algae, Herba Bulbophylli Odoratissim 12 parts, husky Rhizoma Zingiberis Recens 12 parts, Sarcococca ruscifolia Stapf 3 parts, Periostracum Cicadae 12 parts, Mytilus 3 parts.
Embodiment 3, crude drug weight proportion: Eriocheir sinensis 73 parts, Fructus Piperis Longi 9 parts, Fructus Polygoni Orientalis 5 parts, Folium eucalypti globueli (Eucalyptus globulus Labill.) 12 parts, extra large 25 parts, alizarin algae, Herba Bulbophylli Odoratissim 3 parts, husky Rhizoma Zingiberis Recens 20 parts, Sarcococca ruscifolia Stapf 12 parts, Periostracum Cicadae 20 parts, Mytilus 12 parts, Melilotus suaveolens Ledeb. 20 parts, Fructus Leonuri 12 parts.
The Chinese medicine of embodiment 2,3 can be prepared from by following method:
(1) Fructus Piperis Longi, Fructus Leonuri, Folium eucalypti globueli (Eucalyptus globulus Labill.), Sarcococca ruscifolia Stapf, Periostracum Cicadae, Fructus Polygoni Orientalis, Sha Jiang, Melilotus suaveolens Ledeb. coarse powder are extracted volatile oil respectively, and mixing for standby use after collecting, medicinal residues are for subsequent use;
(2) the medicinal residues mixing in Herba Bulbophylli Odoratissim, Eriocheir sinensis seven, Hai Qianzao, Mytilus and step 1 is added the water of 3 times amount, decoct 2 times, each 1 hour, collecting decoction, leave standstill and filter, obtain filtrate for subsequent use;
(3) filtrate will obtained in step 2, is heated to 90 DEG C, natural cooling after 30min, 4 DEG C of cold preservation 30min, filters;
(4) step 3 gained filtrate is filtered with 0.22 μm of microporous filter membrane.
Wherein, the method extracting volatile oil in step 1 can be vapor distillation extraction method.
Clinical interrelated data is as follows.
1 object and method.
1.1 objects: patient 97 example of one-sided cancerous hydrothorax occurs year March first in March, 2010 ~ 2014, get rid of congestive heart failure, actute infection, have pulmonary tuberculosis medical history, have more than half thorax stripping of the pleura history, the patient giving the glucocorticoid treatment of whole body in 2 weeks in the past, and mark 0 ~ 3 point according to east tumor cooperative groups (ECOG), expection time-to-live >6m, kamofsky scoring >60 divides.Patient's ordinary circumstance is: man 66 example, female 31 example; 42 ~ 71 years old age, year mean age (58.9 ± 11.3).97 routine patients are divided into matched group 32 example, hot infusion liquid I group 32 example and hot infusion liquid II group 33 example at random.Compare in sex, age, the state of an illness before three groups of patient treatments, no significant difference (P>0.05), has comparability.
1.2 method.
1.2.1 Therapeutic Method: all patients all adopt the hot infusion therapy mode in thoracic cavity to implement treatment.
The hot method for filling in thoracic cavity: application CT and B ultrasonic check chest, understand hydrothorax amount and position, after placing upper and lower two ductus thoracicuss, patient is helped to get lateral position, open lower breast Tube Drain, after gradation drains hydrothorax, apply the 1000ml infusion liquid prepared and be heated to 45 DEG C are injected into patient affected part through upper ductus thoracicus, ductus thoracicus is clamped after injection, advise patient repeatedly to change position, be beneficial to medicine and fully contact with pleura, after retaining 1h, open lower breast Tube Drain, makes indwelling infusion liquid thoroughly drain.After 1st treatment terminates, upper ductus thoracicus folder closes, and lower ductus thoracicus connects closed drainage of pleural cavity, and interval row the 2nd treatment again in 48 hours, treats three times altogether.
The selection of thoracic infusion liquid: the infusion liquid of matched group is normal saline.Hot infusion liquid I group is the hot infusion liquid of embodiment 1 gained, and its concentration is 94g(crude drug)/L.Hot infusion liquid II group is the hot infusion liquid of embodiment 3 gained, and its concentration is 153g(crude drug)/L.
1.2.2 observation index: treatment effectiveness evaluation after treatment end 4 weeks, treat hydrothorax recurrence in half a year.
1.2.3 treatment effectiveness evaluation method is divided into according to WHO regulation curative effect: complete incidence graph (CR): after treatment, hydrothorax disappears completely, and symptom complete incidence graph uncomfortable in chest, out of breath, has no sepage through x-ray, ultrasound diagnosis, maintains more than 4 weeks; Partial rcsponse (PR): hydrothorax reduces more than 1/2, and symptom is obviously improved, and maintains more than 4 weeks; Invalid (NR): reduce less than 1/2 through treatment hydrothorax or increase, symptom is without improvement or increase the weight of.Total effective rate is calculated with CR+PR.
1.2.4 statistical analysis: SPSS 16.0 carries out statistical analysis.Measurement data t checks, enumeration data χ
2inspection.
2 results.
2.1 treatment end treatment effectiveness evaluation after 4 weeks: curative effect sees the following form,
| Group | Number of cases | CR | PR | NR | Total effective rate |
| Matched group | 32 | 8 | 9 | 15 | 53.13% |
| Hot infusion liquid I group | 32 | 15 | 11 | 6 | 81.25% |
| Hot infusion liquid II group | 33 | 16 | 12 | 5 | 84.85% |
As seen from the above table, hot infusion liquid I group and hot infusion liquid II group total effective rate are higher than matched group, and gap has statistical significance (χ
2=5.74, P<0.05; χ
2=7.67, P<0.01).
2.2 treat hydrothorax recurrence in half a year: matched group incidence rate is 15.63%(5/32), hot infusion liquid I group is 6.25%(2/32), hot infusion liquid II group is 3,03%(1/33), hot infusion liquid I group and hot infusion liquid II group hydrothorax relapse rate are lower than matched group.
2.3 3 groups of adverse reactions of patients incidence rates compare: three groups obvious thoracic infusion related reactions does not all occur, and before and after treatment, hemogram, hepatic and renal function are without significant change.
3. conclusion.
This result of study shows, use hot infusion liquid I group of the present invention and hot infusion liquid II group total effective rate apparently higher than matched group, and hydrothorax relapse rate is lower than matched group, illustrate that prescription of the present invention has the advantage that untoward reaction is comparatively light, safety is higher in treatment cancerous hydrothorax.
Claims (1)
1. for a medicine for thoracic cavity thermo-chemotherapy, it is characterized in that being prepared from by the crude drug of following weight proportion: Eriocheir sinensis 71 ~ 3 parts, Fructus Piperis Longi 6 ~ 9 parts, Fructus Polygoni Orientalis 1 ~ 5 part, Folium eucalypti globueli (Eucalyptus globulus Labill.) 12 ~ 20 parts, extra large 10 ~ 25 parts, alizarin algae, Herba Bulbophylli Odoratissim 3 ~ 12 parts, husky Rhizoma Zingiberis Recens 12 ~ 20 parts, Sarcococca ruscifolia Stapf 3 ~ 12 parts, Periostracum Cicadae 12 ~ 20 parts, Mytilus 3 ~ 12 parts.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510037776.5A CN104645178A (en) | 2015-01-26 | 2015-01-26 | Drug for intrapleural hyperthermic perfusion therapy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510037776.5A CN104645178A (en) | 2015-01-26 | 2015-01-26 | Drug for intrapleural hyperthermic perfusion therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104645178A true CN104645178A (en) | 2015-05-27 |
Family
ID=53237147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510037776.5A Pending CN104645178A (en) | 2015-01-26 | 2015-01-26 | Drug for intrapleural hyperthermic perfusion therapy |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104645178A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101940708A (en) * | 2010-09-14 | 2011-01-12 | 曹锋 | Traditional Chinese medicinal preparation for curing malignant pleural effusion |
| CN104258178A (en) * | 2014-08-28 | 2015-01-07 | 吕彦丽 | Medicine for treating lung cancer pleural effusion and preparation method of medicine |
-
2015
- 2015-01-26 CN CN201510037776.5A patent/CN104645178A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101940708A (en) * | 2010-09-14 | 2011-01-12 | 曹锋 | Traditional Chinese medicinal preparation for curing malignant pleural effusion |
| CN104258178A (en) * | 2014-08-28 | 2015-01-07 | 吕彦丽 | Medicine for treating lung cancer pleural effusion and preparation method of medicine |
Non-Patent Citations (2)
| Title |
|---|
| 刘敏: "艾迪注射液胸腔灌注治疗非小细胞性肺癌恶性胸水临床观察", 《辽宁中医药大学学报》 * |
| 刘铭秋等: "中西医结合治疗恶性胸腔积液58例", 《实用中医药杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102210820A (en) | Chinese medicinal composition for treating leukemia | |
| CN103961553A (en) | Medicine for treating side effects of anesthetics and preparation method of medicine | |
| CN103751482A (en) | Medicine for treating postpartum abdominal pain and preparation method thereof | |
| US20040219226A1 (en) | Complex prescription of Chinese medicine for the treatment of extensive cancer | |
| CN103041341B (en) | Traditional Chinese medicine composition for curing tuberculous exadative pleurisy and preparation method thereof | |
| CN102114230A (en) | Medicament for treating psoriasis | |
| CN108355042A (en) | A kind of anti-inflammatory analgetic ointment and preparation method thereof | |
| CN104095116A (en) | Tea capable of alleviating bone cancer | |
| CN103656048A (en) | Drug for treating cow mastitis and preparation method thereof | |
| CN103623246B (en) | A kind of Chinese medicine preparation for the treatment of hypertension and complication thereof | |
| CN103623198B (en) | Treatment compound medicines oil scalding burn and preparation method thereof | |
| CN105213876A (en) | A kind of medicament for treating insomnia and preparation method thereof | |
| CN104645178A (en) | Drug for intrapleural hyperthermic perfusion therapy | |
| CN105597012A (en) | Traditional Chinese medicine composition for nourishing spleen and enriching stomach and preparation method of traditional Chinese medicine composition | |
| CN104667088A (en) | Preparation method of intrapleural hyperthermal infusion fluid | |
| CN105343866A (en) | Traditional Chinese medicine tablets for treating cold rheum coughs and preparation method | |
| CN104606446A (en) | Pleural lavage fluid for treating post-traumatic acute pyothorax | |
| CN108403910A (en) | A kind of tea medicine for treating eczema | |
| CN104524390A (en) | Thoracic injection for treating postoperative chylothorax | |
| CN107397860A (en) | A kind of anti-tumor biological Chinese medicine preparation and processing technology | |
| CN104435865A (en) | Chinese medicine preparation for treating arrhythmia and preparation method | |
| CN105770759A (en) | Traditional Chinese medicine for treating appendicitis | |
| CN104689014A (en) | Preparation method of pleural lavage fluid | |
| CN104547821A (en) | Perfusion solution for controlling malignant pleural effusion | |
| CN104547820A (en) | Preparation method of medicament for perfusion treatment of malignant pleural effusion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150527 |
|
| WD01 | Invention patent application deemed withdrawn after publication |